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ABSTRACT
Background and Aims. Tegaserod is a selective serotonin receptor (5-HT4) agonist that relieves dysmotility
symptoms associated with constipation. Here we explore its effects on functional dyspepsia symptoms and heartburn
during continued proton pump inhibitor (PPI) treatment.
Methods. In this multicenter pilot study, following a 2-week screening/baseline period, women with functional
dyspepsia and persisting heartburn treated with PPIs received add-on open-label tegaserod 6 mg twice daily (bid) for
4 weeks. Treatment responders were then randomized 1:1 to continue double-blind tegaserod or placebo therapy for
6 weeks. Efﬁcacy variables included the proportion of days with satisfactory relief of dyspepsia symptoms (early
satiety, postprandial fullness and bloating) as well as the change in individual symptom severity scores for these three
cardinal dyspepsia symptoms. Health-related quality of life was evaluated using a validated questionnaire, the
Nepean Dyspepsia Index. Adverse events (AEs) were monitored.
Results. Of 101 women enrolled, 71 completed open-label treatment, and 70 responders were randomized to
double-blind treatment. The proportion of days with satisfactory relief of dyspepsia symptoms (least squares mean,
LSM) increased with tegaserod and placebo, to 0.69 and 0.62, respectively at study end (P = 0.366). Similarly, both
groups showed improvements in the composite daily symptom severity score (overall LSM change from baseline of
1.55 and 1.57, P = 0.934), and the Nepean Dyspepsia Index (overall LSM change of -39.0 and -37.8, P = 0.537).
Tegaserod was well tolerated. Diarrhea was the most common AE (8.1% tegaserod, 0% placebo). There were no
serious AEs or deaths.
Conclusions. A signiﬁcant treatment effect was not demonstrated in this study using a treatment-withdrawal
methodology. In future studies of functional dyspepsia patients with heartburn, a more rigorous parallel-group study
design should be considered.
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Introduction
S
ymptoms of heartburn and/or dyspepsia are
reported by an estimated 10–40% of the
population in Western countries [1–3]. Dyspepsia
refers to a group of symptoms (postprandial full-
ness, early satiety, epigastric pain, epigastric
burning, bloating) that are considered by most
physicians to originate from the gastroduodenal
region of the stomach and is further deﬁned as
“functional dyspepsia” if standard investigations
do not provide an explanation for symptoms.
Heartburn is deﬁned by the presence of a ret-
rosternal burning sensation, which tends to move
cephalad into the neck. Functional heartburn is
diagnosed when the heartburn is not accompanied
by evidence of gastroesophageal reﬂux disease
(GERD) as evaluated by endoscopy or 24-hour
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burn may occur concomitantly with dyspepsia
symptoms and such overlap has been illustrated in
a study of gastrointestinal (GI) symptoms in 67
patients with functional heartburn. Sixty-four
percent of functional heartburn patients in this
study had upper abdominal pain, 80% had upper
abdominal discomfort, and 60% had early satiety
[4].
Little is known about the pathophysiology of
the overlapping symptoms of functional dyspepsia
and functional heartburn. Consequently, the most
appropriate therapeutic targets have yet to be
deﬁned, and current treatment options are limited.
Proton pump inhibitors (PPIs) are often pre-
scribed speciﬁcally for the relief of heartburn
and upper abdominal pain. Although predictable
improvements in these two symptoms have been
demonstrated in acid-related conditions, PPI
therapy appears to offer little beneﬁt for patients
with functional dyspepsia and/or functional heart-
burn [5,6].
Tegaserod is a selective serotonin type 4 re-
ceptor (5-HT4) agonist that has been shown to
relieve dysmotility symptoms associated with irri-
table bowel syndrome with constipation (IBS-C)
and chronic idiopathic constipation [7,7–11]. Fur-
thermore, clinical trials have shown that tegas-
erod enhances gastric emptying, accelerates GI
transit in healthy subjects [12], normalizes gastric
emptying in functional dyspepsia patients with
delayed gastric emptying [13], and increases
gastric accommodation and compliance [14,15].
As most functional dyspepsia studies to date have
focused on measuring the pharmacodynamic
effects of tegaserod alone, there are very limited
data available regarding the effects of this agent
on symptom improvement and other patient-
assessed outcomes. This is particularly true for
functional dyspepsia patients with overlapping
functional heartburn who are already receiving
PPI treatment.
Therefore, a pilot study was designed to explore
the possible effects of treatment with tegaserod
6 mg twice daily (bid) vs. placebo in women with
overlapping symptoms of functional dyspepsia and
functional heartburn who had received unsuccess-
ful PPI treatment for their dyspeptic symptoms.
Methods
Study Design
This was a 12-week exploratory multicenter
pilot study of women with functional dyspepsia
and functional heartburn receiving PPIs whose
functional dyspepsia symptoms responded to
open-label tegaserod treatment. Responders to
open-label tegaserod treatment were randomized
to double-blind, placebo-controlled withdrawal of
tegaserod while PPI treatment was continued
(Figure 1).
All subjects were required to have had a nega-
tive upper GI endoscopy performed within the
preceding 24 months at a time when their func-
tional dyspepsia and functional heartburn symp-
toms were active. Following a 2-week screening/
baseline assessment phase, all eligible patients
received open-label treatment with tegaserod
6 mg bid for 4 weeks, which was added to their
current PPI regimen. Treatment responders were
identiﬁed based on their response during the last
week of open-label treatment to a weekly Global
Figure 1 Study design.
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ponders were then randomized 1:1 to receive
tegaserod 6 mg bid or placebo bid for 6 weeks, i.e.,
the patients either continued to receive tegaserod/
PPI therapy or were switched to placebo/PPI
therapy. Documentation conﬁrming the continu-
ation of a stable PPI therapy regimen was required
throughout the study in both groups.
Randomization assignment was performed by
the study sponsor using a validated system that
automates the random assignment of the subjects
to the two treatment groups. The randomization
scheme and the randomization number code for
individual patients was locked after approval by
a Biostatistics Quality Assurance Group and
remained conﬁdential until required for data
analysis following study completion. Patients and
study investigators remained blinded to treatment
throughout the study. Blinding was maintained
using placebo and tegaserod tablets of identical
appearance and packaging the tablets in containers
that were also identical in appearance.
The study protocol was approved by an In-
stitutional Review Board/Independent Ethics
Committee/Research Ethics Board at each partici-
pating center and performed according to the
Declaration of Helsinki and the principles of
Good Clinical Practice. All patients gave written
informed consent before participating in the study.
The study is registered under the ClinicalTrials.
gov number: NCT00171470.
Patient Population
Women (18 years) receiving PPI therapy at
stable doses for at least 4 weeks for heartburn were
enrolled in this study if they had self-reported
symptoms of functional dyspepsia (mid–upper
abdominal discomfort associated with post-meal
fullness, early satiety while eating and bloating, as
well as abdominal pain, nausea, vomiting, regurgi-
tation or constipation) for at least 12 weeks (not
necessarily consecutive) during the previous 12
months (Rome II criteria for functional dyspepsia)
[16]. Starting at screening/baseline and continuing
throughout the study, patients rated their discom-
fort caused by their functional dyspepsia symp-
toms on a daily basis using a 7-point scale (0 = no
discomfort at all, 1 = minimal discomfort, 2 = mild
discomfort, 3 = moderate discomfort, 4 = moder-
ately severe discomfort, 5 = severe discomfort,
6 = very severe discomfort). In order to qualify for
inclusion, patients’ average symptom severity
score was required to be at least “mild” for two or
more of the following functional dyspepsia symp-
toms: post-meal fullness, early satiety while eating,
and bloating. To enter the study, patients were also
required to report a lack of satisfactory relief of
dyspeptic symptoms during both of the 2 weeks of
screening/baseline. This was based on a response
of “No” to the weekly Global Symptom Assess-
ment question:
Over the past week, did you have satisfactory relief of
your mid–upper abdominal discomfort which may
include early fullness (early satiety) while eating, post-
meal fullness, or bloating? (Yes or No)
Key exclusion criteria were a history of erosive
esophagitis or peptic ulcer disease, intestinal
obstruction, symptomatic gallbladder disease,
sphincter of Oddi dysfunction, or abdominal adhe-
sions; a history of major abdominal surgery affect-
ing GI anatomy; evidence of acute or serious
medical conditions other than dyspepsia or evi-
dence that dyspeptic symptoms are relieved by
defecation and/or associated with a change in stool
frequency or stool form. Heartburn as the current
most bothersome symptom also resulted in exclu-
sion from the study, as did receiving ulcer preven-
tion treatment with acid suppressive therapy. A
history of frequent or chronic diarrhea, or treat-
ment for Helicobacter Pylori within the previous 6
months, were also exclusions. In addition, preg-
nant or breastfeeding women, and those of child-
bearing age who were not using an approved
method of contraception, were excluded. Prior
treatment with medications that could mask the
effect of the trial medication was disallowed.
These medications included systemic cholinergics
and anticholinergics (e.g., l-hyoscyamine, clidi-
nium, dicyclomine), calcium channel blockers
(e.g., verapamil, amlodipine), narcotic analgesics,
nitroglycerin derivatives, prokinetics (e.g., meto-
clopramide), macrolide antibiotics, and histamine
H2 receptor antagonists. Patients were permitted
rescue medication with sodium bicarbonate,
sodium alginate, and/or calcium carbonate.
Efﬁcacy Assessments
Patients completed diaries throughout the three
study phases (screening/baseline, open-label and
double-blind). During the screening/baseline
phase they recorded their responses to the follow-
ing Global Symptom Assessment question on a
weekly basis:
Over the past week, did you have satisfactory relief of
your mid–upper abdominal discomfort which may
include early fullness while eating, post-meal fullness,
or bloating? (Yes or No)
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blind phases, a daily diary entry was required for a
similar Global Symptom Assessment question:
Today, did you have satisfactory relief of your mid–
upper abdominal discomfort which may include
early fullness while eating, postprandial fullness, or
bloating? (Yes or No)
In their daily diary, patients also recorded the
severity of their individual symptoms. This was a
daily occurrence throughout all three study phases
to quantitate each patient’s assessment of the dis-
comfort caused by the speciﬁc functional dyspepsia
and functional heartburn symptoms (early satiety
while eating, post-meal fullness, bloating, abdomi-
nalpain,nausea,heartburn,regurgitation,andcon-
stipation). The symptom assessment was captured
using a 7-point scale (Rome II criteria) [16] which
ranged from a score of 0 = no discomfort at all to a
score of 6 = very severe discomfort.
To be entered into the study, patients had to
answer “No” to the weekly Global Symptom
Assessment question for both weeks of the 2-week
screening/baseline phase. After study entry, the
primaryefﬁcacyvariablewastheproportionofdays
with satisfactory relief of dyspepsia during the
double-blind phase based on the daily Global
SymptomAssessmentquestion.Thiswasdeﬁnedas
the number of days in which the patient responded
“Yes” to the Global Symptom Assessment question
divided by the number of days the question was
answered. Secondary variables included the aver-
age daily severity score of three key symptoms
during the double-blind phase (early satiety while
eating,post-mealfullnessandbloating).Symptoms
wereassessedbothasadailycompositescoreforthe
three key functional dyspepsia symptoms (mean
severity value across all three symptoms), and as
average daily scores for the individual symptoms
(only daily composite functional dyspepsia sym-
ptom score data are reported here).
Patients were also asked to complete a vali-
dated, disease-speciﬁc quality of life instrument,
the Short Form-Nepean Dyspepsia Index ques-
tionnaire (SF-NDI) [17,18]. This was done at each
study visit (Day 0, Day 29, Day 50, and Day 71 or
early discontinuation).
Safety Assessments
All adverse events (AEs) were recorded and moni-
tored. An AE was deﬁned as any undesirable sign,
symptom, or medical condition occurring after
starting study drug even if the event was not con-
sidered to be related to study drug. In addition,
patients’ vital signs, blood chemistry and hematol-
ogy were measured and electrocardiogram (ECG)
evaluations were performed at screening/baseline
and end of study.
Statistical Analyses
All statistical tests were conducted against a two-
sided alternative hypothesis, employing a signiﬁ-
cance level of 0.05.
The intent-to-treat (ITT) population com-
prisedallrandomizedpatientswhoreceivedatleast
onedoseofstudydrugpost-randomizationandhad
atleastonepost-baselineassessmentoftheprimary
efﬁcacy variable. The safety population, compris-
ing all patients who received at least one dose of
study drug, was used for all safety analyses.
The primary efﬁcacy variable was analyzed for
the ITT population using an analysis of covariance
(ANCOVA) model that included treatment,
center, and proportion of days with satisfactory
relief during screening/baseline as explanatory
variables. Least squares mean (LSM) values, LSM
treatment differences and 95% conﬁdence inter-
vals (CI) for the difference in the two treatments
were reported, based on the ﬁtted linear model. To
assess the impact of missing data on the proportion
of days with satisfactory relief, a sensitivity analysis
was performed which imputed “non-response” for
patients who did not complete at least half (21
days) of the assessments. In addition to evaluating
the effect over the entire double-blind treatment
phase, the primary efﬁcacy variable was analyzed
similarly for each study week.
The analysis of average daily severity scores for
early satiety while eating, post-meal fullness, and
bloating was similar to that for the primary efﬁcacy
variable. The three symptom severity scores were
averaged on a daily basis and then a grand mean
value was calculated using all available data during
the double-blind treatment phase.
Change from baseline in the total score and
each domain score of the SF-NDI was analyzed
using an ANCOVA model that included center
and baseline as explanatory variables.
The sample size for this pilot study was not
based on statistical power considerations. All sta-
tistical analyses were performed using SAS soft-
ware, Version 8.2.
Results
Patients
A total of 101 patients receiving PPI therapy quali-
ﬁed for and entered the study. Of these patients, 71
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judged to meet the criteria for study randomiza-
tion as tegaserod responders and thus entered
the double-blind treatment phase (Figure 2). The
main reasons for discontinuation during the open-
label treatment phase were AEs (n = 9), protocol
violations (n = 8), and unsatisfactory therapeutic
effect (n = 6).
Baseline demographics of the populations ran-
domized to the two treatments were comparable
and their characteristics were consistent with those
of the overall study population (Table 1). As may
be expected following selection of an enriched
population of treatment responders, there were
few discontinuations during the double-blind
phase (n = 4). The discontinuations were due to
unsatisfactory therapeutic effect (tegaserod n = 2
and placebo n = 1) and withdrawal of consent
(tegaserod n = 1).
Efﬁcacy
Days with Satisfactory Relief of Functional
Dyspepsia Symptoms
The LSM proportion of days with satisfactory
relief of functional dyspepsia symptoms during the
double-blind phase for the ITT population was
0.69 in the tegaserod group vs. 0.62 in the placebo
group (P = 0.366; Table 2). This difference was not
statistically signiﬁcant. Evaluation of the propor-
tion of days with satisfactory relief for the ITT
population during each separate study week also
showed no signiﬁcant differences between groups,
with LSM treatment differences at each week
ranging from -0.028 to 0.127 (Table 2). Table 3
shows the effect of double-blind treatment on dys-
pepsia symptoms for the primary efﬁcacy variable,
the proportion of days with satisfactory relief of
symptoms, indicating that there were negligible
differences between the tegaserod and placebo
groups.
Composite Daily Symptom Severity Score
In line with the ﬁndings observed for the primary
efﬁcacy variable, the combined average daily sever-
ity score of the three key symptoms (early satiety
while eating, post-meal fullness, and bloating) for
the ITT population during the double-blind phase
did not differ signiﬁcantly between treatment
groups (Table 2). The LSM average daily severity
score was 1.55 in the tegaserod group and 1.57 in
the placebo group, representing a LSM treatment
difference of -0.017 (P = 0.934). Similar results
were observed for each of the three key symptoms
when analyzed separately.
Figure 2 Summary of patient ﬂow.
*Received at least one dose of study
medication.
†Received at least one
dose of study medication post-
randomization and had at least one
post-baseline assessment of primary
efficacy variable.
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Index (SF-NDI)
SF-NDI total score and domain scores in the ITT
population decreased (indicating an improvement)
in both the tegaserod and placebo groups, from
LSM scores of -39.9 and -36.4 (P = 0.102),
respectively, at Day 50, to -39.0 and -37.8
(P = 0.537), respectively, at Day 71 (end of study;
Table 4). There were no statistically signiﬁcant
differences in response between the two treatment
groups.
Safety
Treatment with tegaserod during both the open-
label, and double-blind phases was well tolerated,
with few AEs and no serious AEs reported. The
Table 1 Baseline patient characteristics
Variable
All patients in
open-label phase Patients randomized to double-blind treatment
Tegaserod Tegaserod Placebo
(N = 101) (N = 37) (N = 33)
Age, years
Mean  SD 48.6  14.8 47.9  14.3 48.7  16.1
Minimum, maximum 18, 80 19, 80 18, 73
Ethnic origin, n (%)
Caucasian 71 (70.3) 27 (73.0) 23 (69.7)
African American 6 (5.9) 2 (5.4) 2 (6.1)
Asian 12 (11.9) 5 (13.5) 3 (9.1)
Other 12 (11.9) 3 (8.1) 5 (15.2)
Most common GI disorders,* n (%)
GERD 52 (51.5) 23 (62.2) 15 (45.5)
Dyspepsia 49 (48.5) 16 (43.2) 17 (51.5)
Hiatus hernia 30 (29.7) 9 (24.3) 11 (33.3)
Constipation 22 (21.8) 9 (24.3) 9 (27.3)
Hemorrhoids 13 (12.9) 5 (13.5) 3 (9.1)
Other common conditions,
† n (%)
Hysterectomy 30 (29.7) 9 (24.3) 12 (36.4)
Asthma 22 (21.8) 4 (10.8) 10 (30.3)
Hypertension 19 (18.8) 7 (18.9) 7 (21.2)
Headache 18 (17.8) 7 (18.9) 7 (21.2)
Drug hypersensitivity 16 (15.8) 8 (21.6) 3 (9.1)
Cholecystectomy 14 (13.9) 3 (8.1) 7 (21.2)
Osteoarthritis 9 (8.9) 0 7 (21.2)
*Reported by 10% of patients in any group.
†Reported by 20% of patients in any group.
Table 2 Effect of double-blind treatment on dyspepsia symptoms in women receiving PPI therapy: primary efficacy
variable (ITT population*)
Least squares mean
P value
95% CI for
treatment difference
Tegaserod
†
(N = 36)
Placebo
†
(N = 33)
Treatment
difference
Proportion of days with
satisfactory relief
‡ of
symptoms (ALL WEEKS)
0.69 0.62 0.069 0.366 (-0.083, 0.222)
Start of double-blind phase
Week 7 0.73 0.62 0.110 0.201 (-0.060, 0.279)
Week 8 0.73 0.61 0.127 0.181 (-0.061, 0.315)
Week 9 0.70 0.60 0.100 0.260 (-0.076, 0.275)
Week 10 0.68 0.60 0.087 0.341 (-0.095, 0.269)
Week 11 0.66 0.65 0.001 0.989 (-0.181, 0.184)
End of double-blind phase
Week 12 0.69 0.72 -0.028 0.773 (-0.222, 0.166)
*Received at least one dose of study medication post-randomization and had at least one post-baseline assessment of primary efficacy variable.
†Estimated by analysis of covariance adjusted for center and baseline values.
‡Deﬁned as a response of “Yes” to the weekly Global Symptom Assessment question: “Over the past week, did you have satisfactory relief of your mid–upper
abdominal discomfort which may include early fullness (early satiety) while eating, post-meal fullness, or bloating?”
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patients in the open-label phase (14.9%). In the
double-blind phase, diarrhea was reported by
three patients in the tegaserod group (8.1%) and
none in the placebo group (Table 5).
Hypertension was the only cardiovascular-
related AE reported in this study (n = 3), and was
experienced by two patients in the open-label
phase, and one patient in the double-blind phase
(this patient had been randomized to tegaserod).
Although most AEs were “mild” or “moderate”
in severity, six patients (5.9%) reported severe AEs
during the open-label phase (three GI disorders,
one migraine headache, one asthma and one
arthralgia). During the double-blind phase, two
patients in the tegaserod group (2.7%, bronchitis
and GERD) and one patient in the placebo group
(3.0%, abdominal pain) reported an AE of severe
intensity.
AEs were generally considered by study inves-
tigators to be unrelated to study drug. Treatment-
related AEs were reported for only three patients
(8.1%) in the tegaserod group (abdominal pain,
diarrhea, ﬂatulence, nausea: one patient reported
two AEs) and one patient (3.0%) in the placebo
group (abdominal pain).
Nine patients discontinued from the open-label
phase of the study due to AEs (the most frequent
being diarrhea, n = 4, 4%). No patients discon-
tinued treatment due to an AE during the double-
blind phase. There were no clinically relevant
changes in vital signs, blood chemistry, hematol-
ogy, or ECG examinations and no patients died
during the study.
Table 3 Effect of double-blind treatment on dyspepsia symptoms in women receiving PPI therapy: primary efficacy
variable (mean  SD; ITT population*)
Proportion of days with
satisfactory relief
† of
symptoms Tegaserod (N = 36) Placebo (N = 33)
Baseline Week 1 0.07  0.15 0.11  0.19
Week 2 0.07  0.16 0.06  0.16
Open-label phase Week 3 0.44  0.36 0.47  0.38
Week 6 0.71  0.37 0.86  0.26
Double-blind phase Week 7 0.75  0.32 0.63  0.35
Week 12 0.74  0.37 0.77  0.32
*Received at least one dose of study medication post-randomization and had at least one post-baseline assessment of primary efficacy variable.
†Deﬁned as a response of “Yes” to the weekly Global Symptom Assessment question: “Over the past week, did you have satisfactory relief of your mid–upper
abdominal discomfort which may include early fullness (early satiety) while eating, post-meal fullness, or bloating?”
Table 4 Effect of double-blind treatment on responses to the SF-NDI questionnaire (ITT population)
Time point
Least squares
mean
PPI + tegaserod*
Least squares
mean
PPI + placebo*
Least squares
mean treatment
difference* P value*
95% CI for
treatment
difference*
Total score Day 50 -39.9 -36.4 -3.49 0.102 (-7.70, 0.71)
Day 71
(EOS)
-39.0 -37.8 -1.21 0.537 (-5.13, 2.70)
Tension dimension score Day 50 -7.5 -7.2 -0.34 0.489 (-1.33, 0.65)
Day 71
(EOS)
-7.5 -7.3 -0.16 0.686 (-0.97, 0.64)
Interferences with daily activities Day 50 -7.2 -6.6 -0.61 0.231 (-1.62, 0.40)
Day 71
(EOS)
-7.1 -6.8 -0.27 0.538 (-1.13, 0.60)
Eating/drinking Day 50 -9.1 -8.3 -0.81 0.066 (-1.67, 0.06)
Day 71
(EOS)
-8.6 -8.5 -0.08 0.856 (-0.98, 0.81)
Knowledge/control Day 50 -8.0 -7.3 -0.75 0.071 (-1.57, 0.07)
Day 71
(EOS)
-7.9 -7.5 -0.45 0.322 (-1.36, 0.46)
Work/study Day 50 -8.0 -7.1 -0.88 0.141 (-2.07, 0.30)
Day 71
(EOS)
-7.8 -7.7 -0.11 0.824 (-1.13, 0.90)
*Adjusted mean treatment difference, P value and 95% CI are based on the least squares means in the PPI + tegaserod group minus the PPI + placebo group.
Least squares means in either group were estimated by an analysis of covariance model that adjusted for center and baseline value.
EOS = end of study.
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In addition to their symptoms of dyspepsia (post-
prandial fullness, early satiety, and bloating) some
functional dyspepsia patients also experience
non-acid related heartburn (functional heartburn)
[19]. The Rome Committee recommend that
functional dyspepsia and functional heartburn are
deﬁned as distinct clinical entities; however, they
also recognize that some overlap of symptoms
exists [3,16]. While debate continues on the most
appropriate deﬁnition to apply to functional disor-
ders such as functional dyspepsia and functional
heartburn, what is clear is that symptoms of both
disorders overlap in some patients. Patients may
also present with comorbidity with other GI dis-
orders such as IBS and GERD. This observation is
not surprising as recent studies have suggested that
IBS and functional dyspepsia may share similar
pathological mechanisms [20,21].
Treatments for patients with overlapping symp-
toms of functional dyspepsia and functional heart-
burn are currently suboptimal; while PPIs may be
prescribed as ﬁrst-line therapy in patients with
symptoms of heartburn and dyspepsia, they have
limited efﬁcacy if patients’ symptoms are not acid-
related [6]. Reasons for the lack of efﬁcacy of PPIs
in this patient group are unclear, but may be
explained by the presence of dysmotility symptoms
in patients with non-acid related symptoms or
weakly acidic reﬂux that persists despite PPI
therapy [22]. In addition, difﬁculties in designing
clinical trials that account for the heterogeneity of
functional dyspepsia and functional heartburn
symptoms may have also hampered the develop-
ment of effective treatments [23,24].
Tegaserod is a selective 5-HT4 agonist that has
been shown to improve dysmotility symptoms in
patients with IBS-C and chronic idiopathic consti-
pation [7–11]. Additional studies have suggested it
may also improve some dysmotility symptoms
related to dyspepsia [15,25,26].
The women enrolled in this study were receiv-
ing PPI treatment for their symptoms of heartburn
but without an adequate effect on their dyspeptic
symptoms. A randomized withdrawal study design
was selected in order to enrich the study popula-
tion with patients who may respond to the active
drug being tested, an approach that is considered
to be particularly appropriate for drugs whose
effect may be difﬁcult to assess using other meth-
odologies [27]. This approach was supported by
the exploratory nature of the present study.
The results seen in this exploratory study, while
not supportive, do not allow any deﬁnitive con-
clusions to be made on the role of tegaserod in
women with overlapping functional dyspepsia and
functional heartburn. One possible explanation
could be that tegaserod, in line with the null
hypothesis, may not be different to placebo in
relieving the symptoms captured in this study, and
in this patient population. Another explanation
relates to a possible Type 2 error as the study
(being exploratory) may not have had sufﬁcient
statistical power to demonstrate a beneﬁt for tega-
serod. The study design and sample size was based
on practical reasons including the availability of
resources and the limited timelines. Furthermore,
speciﬁc limitations of a withdrawal study design
may also have contributed to the negative
outcome. In fact, it is conceivable that the com-
bined effect of a relatively small sample size and a
possible carry-over treatment effect from the
open-label phase may mean that the study design
was not sufﬁciently sensitive to detect differences
between the two treatment groups. It is possible
that extending the length of the double-blind
portion of this study may have overcome any
potential carry-over effect.
The patients’ quality of life scores (measured
using the SF-NDI questionnaire) were consistent
with the primary/secondary efﬁcacy variables in
that no treatment difference between tegaserod
and placebo was observed, thus supporting the
validity of the results. Treatment with tegaserod
was well tolerated in this study, a ﬁnding that is
consistent with previous studies in IBS-C, chronic
idiopathic constipation and functional dyspepsia.
Table 5 Summary of most commonly reported* AEs
during open-label and double-blind phases (safety
population
†)
Event
Open-label phase Double-blind phase
All patients Tegaserod Placebo
(N = 101) (N = 37) (N = 33)
Any AE
‡, n (%) 32 (31.7) 12 (32.4) 8 (24.2)
Diarrhea 15 (14.9) 3 (8.1) 0
Sinus congestion 1 (1.0) 2 (5.4) 1 (3.0)
Headache 4 (4.0) 2 (5.4) 0
Abdominal pain 2 (2.0) 1 (2.7) 1 (3.0)
Toothache 1 (1.0) 0 2 (6.1)
Constipation 2 (2.0) 0 1 (3.0)
Flatulence 2 (2.0) 1 (2.7) 0
Nausea 2 (2.0) 1 (2.7) 0
Migraine 2 (2.0) 0 0
Asthma 2 (2.0) 0 0
Hypertension 2 (2.0) 1 (2.7) 0
*Reported by 2 patients in any group.
†All patients who received at least one dose of study medication.
‡Patients may have reported more than one AE.
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and as tegaserod is an agent with promotile activity
in the GI tract, diarrhea is an expected treatment
effect.
Since this study was completed, tegaserod was
withdrawn from sale in the US due to a statistically
signiﬁcant imbalance in the incidence of cardio-
vascular ischemic events in patients taking tegas-
erod vs. placebo. Despite there being no access to
tegaserod in normal clinical practice, we felt that
publishing these data may beneﬁt other research-
ers assessing the pharmacological activity of agents
for treating this patient population.
Insummary,whiletheseresultsdonotshowthat
tegaserod relieved the symptoms of dyspepsia in
these patients, no conclusive statement regarding
treatment effect can be made from this pilot study.
Further studies of functional dyspepsia patients
with heartburn should employ a more rigorous and
adequately powered parallel-group study design.
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